Bobin, A., Manier, S., de Keizer, J., Srimani, J. K., Hulin, C., Karlin, L., Caillot, D., Lafon, I., Mariette, C., Araujo, C., Arnulf, B., Bareau, B., Belhadj, K., Benboubker, L., Braun, T., Calmettes, C., Decaux, O., Dib, M., Demarquette, H., Jacquet, C., Sonntag, C., Godet, S., Jaccard, A., Lenain, P., Macro, M., Richez-Olivier, V., Tiab, M., Vincent, L., Zerazhi, H., Pétillon, M.-O., Rollet, S., Gardeney, H., Durand, G., Levy, A., Touzeau, C., Perrot, A., Moreau, P., Facon, T., Corre, J., Ragot, S., Avet-Loiseau, H. and Leleu, X. (2020) “Ixazomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma characterized with high-risk cytogenetics: the IFM 2014-01 study”, Haematologica. Pavia, Italy. doi: 10.3324/haematol.2024.285916.